Strides’ Puducherry Plant Gets FDA Warning Letter
India’s Strides has received a warning letter from the US Food and Drug Administration over compliance issues at its Puducherry plant. However, the firm has told investors the regulatory action will not affect its forecast of 20% US sales growth for this financial year.
You may also be interested in...
Strides' newly-appointed CEO, R Ananthanarayanan, sees no reason to change course as the firm's current strategy continues to yield positive results. The company posted a 29% increase in third-quarter revenues on the back of 62% growth in the US.
Strides Pharma Science, which has reported a strong second-quarter performance, said its reborn injectables business will “be full-blown” in several markets by December thanks to the expiry of a non-compete agreement with Mylan.
India’s Strides has announced its entry into China through a joint-venture with one of the country’s leading pharmaceutical firms, Sihuan, at the same time as reporting first-quarter EBITDA that soared by 155%.